EA202190593A1 - Расщепленные миметики интерлейкина и их применение - Google Patents
Расщепленные миметики интерлейкина и их применениеInfo
- Publication number
- EA202190593A1 EA202190593A1 EA202190593A EA202190593A EA202190593A1 EA 202190593 A1 EA202190593 A1 EA 202190593A1 EA 202190593 A EA202190593 A EA 202190593A EA 202190593 A EA202190593 A EA 202190593A EA 202190593 A1 EA202190593 A1 EA 202190593A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- splitted
- mimetics
- interleukin
- applications
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/04—Libraries containing only organic compounds
- C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5406—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2026—IL-4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5437—IL-13
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862770152P | 2018-11-20 | 2018-11-20 | |
| PCT/US2019/062198 WO2020106708A1 (en) | 2018-11-20 | 2019-11-19 | Split interleukin mimetics and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202190593A1 true EA202190593A1 (ru) | 2021-11-18 |
Family
ID=69500815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202190593A EA202190593A1 (ru) | 2018-11-20 | 2019-11-19 | Расщепленные миметики интерлейкина и их применение |
Country Status (13)
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12247060B2 (en) | 2018-01-09 | 2025-03-11 | Marengo Therapeutics, Inc. | Calreticulin binding constructs and engineered T cells for the treatment of diseases |
| EP3765517A1 (en) | 2018-03-14 | 2021-01-20 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| BR112020025287A2 (pt) * | 2018-06-25 | 2021-03-09 | University Of Washington | Projeto de novo de miméticos de interleucina potentes e seletivos |
| WO2020010250A2 (en) | 2018-07-03 | 2020-01-09 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| JP2022511390A (ja) | 2018-11-20 | 2022-01-31 | ユニバーシティ オブ ワシントン | 分割インターロイキン模倣体およびその使用 |
| JP7579795B2 (ja) | 2019-02-21 | 2024-11-08 | マレンゴ・セラピューティクス,インコーポレーテッド | NKp30に結合する抗体分子およびその使用 |
| AU2020226893B2 (en) | 2019-02-21 | 2025-02-27 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to T cell related cancer cells and uses thereof |
| WO2021138474A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| EP4288548A4 (en) * | 2021-02-05 | 2025-01-15 | Dharmacon, Inc. | FUSION PROTEINS FOR CRISPR-BASED TRANSCRIPTION REPRESSION |
| WO2023044318A2 (en) * | 2021-09-15 | 2023-03-23 | Neoleukin Therapeutics, Inc. | Interleukin-2 receptor βeta (il-2rβ) binding polypeptides |
| CA3248133A1 (en) * | 2022-01-24 | 2023-07-27 | Novimmune Sa | COMPOSITION AND METHODS FOR THE SELECTIVE ACTIVATION OF CYTOKINE SIGNALING PATHWAYS |
| CN116948005A (zh) * | 2022-04-16 | 2023-10-27 | 王晓霞 | 一种病毒递送的新型细胞因子及在肿瘤治疗中的应用 |
| CN120787239A (zh) | 2023-03-07 | 2025-10-14 | 中外制药株式会社 | 通过使用支架蛋白进行有条件地激活的受体信号传导 |
| EP4722235A1 (en) * | 2023-05-24 | 2026-04-08 | Nantong Yichen Biopharma. Co. Ltd. | Polypeptide, and conjugate and use thereof |
| IL325764A (en) * | 2023-07-13 | 2026-03-01 | Outpace Bio Inc | Designed interleukin-2 cytokine compositions and methods for use |
| WO2025212606A1 (en) * | 2024-04-01 | 2025-10-09 | Bio-Techne Corporation | Synthetic il-2 polypeptides and conjugates, compositions, and uses thereof |
| WO2026039791A1 (en) * | 2024-08-16 | 2026-02-19 | Regeneron Pharmaceuticals, Inc. | Tumor-targeted split il2 receptor agonists |
| WO2026078029A1 (en) * | 2024-10-10 | 2026-04-16 | F. Hoffmann-La Roche Ag | Splitted interleukin-2 prodrugs and uses thereof |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1015080A (en) | 1908-04-17 | 1912-01-16 | George I Rockwood | Apparatus for operating alarms or other devices. |
| US5229109A (en) | 1992-04-14 | 1993-07-20 | Board Of Regents, The University Of Texas System | Low toxicity interleukin-2 analogues for use in immunotherapy |
| US6955807B1 (en) | 1998-05-15 | 2005-10-18 | Bayer Pharmaceuticals Corporation | IL-2 selective agonists and antagonists |
| US6168785B1 (en) | 1998-07-16 | 2001-01-02 | Institut Pasteur | Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
| GB0019638D0 (en) * | 2000-08-09 | 2000-09-27 | European Molecular Biology Lab Embl | Peptide mimetics |
| IL159215A0 (en) * | 2001-06-07 | 2004-06-01 | Wyeth Corp | A solution of interleukin-13 and methods utilizing the same |
| CN1930300A (zh) | 2004-03-05 | 2007-03-14 | 希龙公司 | 预测患者治疗药物耐受性的体外试验系统 |
| WO2008138017A2 (en) | 2007-05-08 | 2008-11-13 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for modifying t cell immune responses and inflammation |
| CA2813411C (en) | 2010-11-05 | 2016-08-02 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
| WO2012088446A1 (en) | 2010-12-22 | 2012-06-28 | Board Of Trustees Of The Leland Stanford Junior University | Superagonists and antagonists of interleukin-2 |
| US9844582B2 (en) | 2012-05-22 | 2017-12-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents |
| JP6592505B2 (ja) * | 2014-04-24 | 2019-10-16 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト |
| SMT202100146T1 (it) | 2014-04-30 | 2021-05-07 | Pfizer | Coniugati di anticorpo anti-ptk7-farmaco |
| JP6640834B2 (ja) * | 2014-08-11 | 2020-02-05 | デリニア, インコーポレイテッド | 自己免疫疾患の処置のために調節性t細胞を選択的に活性化させる改変il−2変異体 |
| AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
| AU2018226215B2 (en) | 2017-02-24 | 2019-11-21 | Philogen S.P.A. | Immunoconjugates with optimized linkers and orientation |
| AU2018236272B2 (en) | 2017-03-15 | 2022-03-31 | Silverback Therapeutics, Inc. | Benzazepine compounds, conjugates, and uses thereof |
| BR112020025287A2 (pt) | 2018-06-25 | 2021-03-09 | University Of Washington | Projeto de novo de miméticos de interleucina potentes e seletivos |
| US20220000921A1 (en) | 2018-11-20 | 2022-01-06 | Innovative Cellular Therapeutics Holdings, Ltd. | Modified Cell Expressing Therapeutic Agent and Uses thereof |
| JP2022511390A (ja) | 2018-11-20 | 2022-01-31 | ユニバーシティ オブ ワシントン | 分割インターロイキン模倣体およびその使用 |
| US20220370563A1 (en) | 2019-10-25 | 2022-11-24 | Neoleukin Therapeutics, Inc. | Methods of administration of il-2 receptor agonists |
| AU2020414355A1 (en) | 2019-12-24 | 2022-08-11 | Neoleukin Therapeutics, Inc. | Combination therapy using an IL-2 receptor agonist and an immune checkpoint inhibitor |
| CN111040981A (zh) | 2019-12-26 | 2020-04-21 | 南昌大学 | 表达重组IL-2的重组大肠杆菌Nissle 1917及其功能验证方法 |
| EP4121449A2 (en) | 2020-03-16 | 2023-01-25 | Neoleukin Therapeutics, Inc. | Interleukin-2 receptor beta (il-2rb) binding polypeptides |
-
2019
- 2019-11-19 JP JP2021517768A patent/JP2022511390A/ja active Pending
- 2019-11-19 CA CA3119472A patent/CA3119472A1/en active Pending
- 2019-11-19 CN CN201980070569.6A patent/CN112912388A/zh active Pending
- 2019-11-19 AU AU2019384523A patent/AU2019384523B2/en active Active
- 2019-11-19 EA EA202190593A patent/EA202190593A1/ru unknown
- 2019-11-19 MX MX2021005593A patent/MX2021005593A/es unknown
- 2019-11-19 KR KR1020217014525A patent/KR20210094531A/ko not_active Ceased
- 2019-11-19 SG SG11202103045SA patent/SG11202103045SA/en unknown
- 2019-11-19 WO PCT/US2019/062198 patent/WO2020106708A1/en not_active Ceased
- 2019-11-19 CN CN202510054463.4A patent/CN120040576A/zh active Pending
- 2019-11-19 EP EP19848950.2A patent/EP3883956A1/en active Pending
- 2019-11-19 US US17/294,807 patent/US12234572B2/en active Active
- 2019-11-19 BR BR112021008985-3A patent/BR112021008985A2/pt not_active IP Right Cessation
-
2021
- 2021-05-16 IL IL283217A patent/IL283217A/en unknown
-
2024
- 2024-10-07 JP JP2024175673A patent/JP2025013348A/ja active Pending
-
2025
- 2025-01-10 US US19/016,343 patent/US20250179690A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019384523B2 (en) | 2025-08-28 |
| WO2020106708A1 (en) | 2020-05-28 |
| CA3119472A1 (en) | 2020-05-28 |
| JP2022511390A (ja) | 2022-01-31 |
| EP3883956A1 (en) | 2021-09-29 |
| JP2025013348A (ja) | 2025-01-24 |
| US20220017588A1 (en) | 2022-01-20 |
| IL283217A (en) | 2021-06-30 |
| US20250179690A1 (en) | 2025-06-05 |
| SG11202103045SA (en) | 2021-04-29 |
| US12234572B2 (en) | 2025-02-25 |
| CN112912388A (zh) | 2021-06-04 |
| CN120040576A (zh) | 2025-05-27 |
| KR20210094531A (ko) | 2021-07-29 |
| BR112021008985A2 (pt) | 2021-10-26 |
| MX2021005593A (es) | 2021-08-11 |
| AU2019384523A1 (en) | 2021-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020005819A8 (en) | De novo design of potent and selective interleukin mimetics | |
| ZA202307368B (en) | Antibody against human il-4ra and use thereof | |
| MX2021005593A (es) | Miméticos de interleucina dividida y sus usos. | |
| MX2021004270A (es) | Anticuerpos estabilizadores de trem2. | |
| WO2020086647A8 (en) | Ny-eso-1 t cell receptors and methods of use thereof | |
| BR112021017365A2 (pt) | Receptores de citocina quiméricos constitutivamente ativos | |
| MX2018008840A (es) | Moleculas que activan selectivamente celulas t reguladoras para el tratamiento de enfermedades. | |
| IL278090A (en) | IL-15/IL-15Rα heterodimeric Fc-Fc proteins and their uses | |
| MX2020009051A (es) | Receptores de citocina quimericos inducibles. | |
| GB2538666A (en) | Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases | |
| PH12020550661A1 (en) | Partial agonists of interleukin-2 | |
| SA520420262B1 (ar) | أجسام مضادة ضد مستقبل مُطلق معبر على خلايا نقوية-1 واستخداماتها | |
| EA201891589A1 (ru) | Условно активные гетеродимерные полипептиды и способы их применения | |
| MX2021008796A (es) | Anticuerpos contra subunidad alfa il-7r y usos de estos. | |
| EA202091342A3 (ru) | Слитые белки интерлейкин-2/рецептор интерлейкина-2 альфа и способы применения | |
| MX2024001595A (es) | Anticuerpos btla. | |
| EA202190378A1 (ru) | Антитела против ifnar1 для лечения аутоиммунных заболеваний | |
| JOP20220071A1 (ar) | سيتوكين مناعي يشمل معقد بروتين دايمري غير متجانس على أساس IL-15/IL-15Ra | |
| ZA202109182B (en) | Natriuretic peptide receptor 1 antibodies and methods of use | |
| SA519410534B1 (ar) | أجسام مضادة لعامل مساعد لموهن الخلايا الليمفاوية البائية والتائية واستخداماتها | |
| EA202091918A1 (ru) | Car-t клетки и аутоиммунные заболевания | |
| MX2025000992A (es) | Anticuerpos anti-cd40 y usos de los mismos | |
| ZA202401100B (en) | Human interleukin-4 receptor alpha antibodies | |
| PH12022553411A1 (en) | Btla antibodies | |
| NZ763061A (en) | Anti-ox40 antibodies and uses thereof |